1. Scrip
  2. >>Archive

US Capitol Capsule: US anti-bribery actions 'next shoe' in China scandal?

 
• By Donna Young

Drug makers embroiled in the recent bribery allegations in China are likely sweating over whether the next shoe to drop will be US charges under the Foreign Corrupt Practices Act (FCPA), given the Security and Exchange Commission (SEC) has not been shy in going after publicly traded biopharmas the agency determines has violated the law.

Drug makers embroiled in the recent bribery allegations in China are likely sweating over whether the next shoe to drop will be US charges under the Foreign Corrupt Practices Act (FCPA), given the Security and Exchange Commission (SEC) has not been shy in going after publicly traded biopharmas the agency determines has violated the law.

Accusations in the latest scandal in China involving payments to doctors to influence them to prescribe one medicine over another – a practice some have said is commonplace in that nation – have been lodged against GlaxoSmithKline, AstraZeneca, Sanofi, Novartis and most recently Lilly (scripintelligence.com, 12 July 2013, 22 July 2013, 12 August 2013,

More from Archive

Final Chance To Have Your Say: Take Scrip's Reader Survey This Week

 
• By Eleanor Malone

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By Eleanor Malone

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.

Galapagos Expands Point-Of-Care CAR-T Study To The US

 
• By Andrew McConaghie

CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.

Analysts Split On Eisai’s Chances Of Changing EU Regulator’s Mind On Leqembi

 
• By Andrew McConaghie

A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand

More from Scrip

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: AstraZeneca CEO cautions Europe; Pfizer CEO optimistic on US tariffs, pricing; Merck & Co reassures on pipeline; Merck KGaA buys SpringWorks; and Akeso explains ivonescimab overall survival data.

Vertex Sinks On Below-Consensus Revenue, Limited Sales From New Launches

 
• By Mandy Jackson

Vertex is in need of diversification, but in addition to its lower-than-expected Q1 revenue, sales of the company’s newest CF drug Alyftrek and pain medicine Journavx disappointed.

Aldeyra Plans To File Reproxalap Again With New Dry Eye Symptom Data

 
• By Joseph Haas

The biotech hopes a third time will be the charm after two FDA complete responses, with plans to position its eye drop as offering quicker onset of action.